1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt manufacturers
- Allopurinol Sodium
-
- $30.00 / 5mg
-
2026-03-05
- CAS:17795-21-0
- Min. Order:
- Purity: 99.93%
- Supply Ability: 10g
|
| | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt Basic information |
| Product Name: | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt | | Synonyms: | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt;Allopurinolsodium;1H-Pyrazolo[3,4-d]pyrimidin-4-ol monosodium salt;Sodium allopurinol;Allopurinol SodiuM (AlopriM);SodiuM 1H-pyrazolo[3,4-d]pyriMidin-4-olate;Aloprim;1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, sodium salt (1:1) | | CAS: | 17795-21-0 | | MF: | C5H5N4NaO | | MW: | 160.11 | | EINECS: | 241-771-5 | | Product Categories: | Inhibitors | | Mol File: | 17795-21-0.mol | ![1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt Structure](CAS/GIF/17795-21-0.gif) |
| | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt Chemical Properties |
| storage temp. | Sealed in dry,Room Temperature | | form | Solid | | pka | 9.31(at 25℃) | | color | White to off-white |
| | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt Usage And Synthesis |
| Uses | Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect[1][2][3][4][5]. | | in vivo | Allopurinol sodium (39 mg/kg; p.o.; daily for 21 successive days) shows anti-depressant activity in mouse[3].
Allopurinol sodium (10-400 mg/kg; i.p.) induces anti-nociception activity in mouse[4]. | Animal Model: | 20-30 g, male Swiss Albino mice[3] | | Dosage: | 39 mg/kg | | Administration: | P.o.; daily for 21 successive days | | Result: | Reduced the immobility time in the FST with the immobility time of 129.8±10.5 s. |
| Animal Model: | 30-40 g, male adult Swiss albino mice[4] | | Dosage: | 10, 50, 100, 200, 400 mg/kg | | Administration: | I.p. | | Result: | Produced dose-dependent anti-nociception in the tail-flick, hot-plate. |
| | References | [1] Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114. DOI:10.1124/pr.58.1.6
[2] Pfaller MA, et al. Antileishmanial effect of allopurinol. Antimicrob Agents Chemother. 1974;5(5):469-472. DOI:10.1128/AAC.5.5.469
[3] Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45(3):244-7. DOI:10.4103/0253-7613.111922
[4] Schmidt AP, et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol. 2009 Jan;156(1):163-72. DOI:10.1111/j.1476-5381.2008.00025.x
[5] Sun Y, et al. Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. PLoS One. 2015 Apr 1;10(4):e0123649. DOI:10.1371/journal.pone.0123649 |
| | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, monosodium salt Preparation Products And Raw materials |
|